A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,141,500 shares of AVIR stock, worth $3.93 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,141,500
Previous 1,123,400 1.61%
Holding current value
$3.93 Million
Previous $4.54 Million 16.77%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$3.31 - $4.04 $59,911 - $73,124
18,100 Added 1.61%
1,141,500 $3.78 Million
Q1 2024

May 13, 2024

SELL
$3.09 - $4.56 $1.15 Million - $1.7 Million
-372,903 Reduced 24.92%
1,123,400 $4.54 Million
Q4 2023

Feb 13, 2024

BUY
$2.8 - $3.35 $396,933 - $474,902
141,762 Added 10.47%
1,496,303 $4.56 Million
Q3 2023

Nov 14, 2023

SELL
$3.0 - $3.79 $26,523 - $33,507
-8,841 Reduced 0.65%
1,354,541 $4.06 Million
Q2 2023

Aug 11, 2023

BUY
$3.21 - $5.06 $2.04 Million - $3.22 Million
635,682 Added 87.35%
1,363,382 $5.1 Million
Q1 2023

May 12, 2023

BUY
$3.0 - $4.97 $321,300 - $532,287
107,100 Added 17.26%
727,700 $2.44 Million
Q4 2022

Feb 13, 2023

BUY
$4.35 - $6.17 $100,919 - $143,144
23,200 Added 3.88%
620,600 $2.99 Million
Q3 2022

Nov 14, 2022

SELL
$5.49 - $8.79 $360,144 - $576,624
-65,600 Reduced 9.89%
597,400 $3.4 Million
Q2 2022

Aug 12, 2022

SELL
$5.33 - $8.18 $2.68 Million - $4.11 Million
-502,000 Reduced 43.09%
663,000 $4.71 Million
Q1 2022

May 13, 2022

BUY
$5.5 - $9.19 $2.99 Million - $5 Million
544,200 Added 87.66%
1,165,000 $8.41 Million
Q4 2021

Feb 11, 2022

BUY
$7.67 - $44.59 $4.59 Million - $26.7 Million
598,200 Added 2646.9%
620,800 $5.55 Million
Q3 2021

Nov 12, 2021

BUY
$21.33 - $35.06 $482,057 - $792,356
22,600 New
22,600 $792,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $286M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.